19:10 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Patient sample and mouse studies suggest inhibiting PAK1 and PAK2 could help treat colitis. In samples from patients with inflammatory bowel disease (IBD), levels of a PAK1-induced gene signature were higher in inflamed...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibiting PAK1 or PAK4 could help treat drug-resistant BRAF-mutant melanoma. In tumor samples from metastatic melanoma patients, high primary tumor levels of PAK1 were associated...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1)

Hepatic disease INDICATION: Liver fibrosis Cell culture and mouse studies suggest inhibiting YAP1 or PAK1 could help treat liver fibrosis. In activated rat primary liver myofibroblasts, the YAP1 inhibitor Visudyne verteporfin or a PAK1 inhibitor...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Neurofibromatosis p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies identified PAK1 inhibitors that could help treat neurofibromatosis type 2 (NF2). PAK1...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer b-Catenin (CTNNB1); HER2 (EGFR2; ErbB2; neu); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies suggest...
08:00 , Feb 14, 2013 |  BC Innovations  |  Targets & Mechanisms

Statins for fragile X

Researchers at the Massachusetts Institute of Technology have mouse data showing that the cholesterol drug lovastatin can correct fragile X syndrome. 1 The findings add to a growing list of unconventional strategies for treating this...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Afraxis, Genentech, Roche deal

Roche's Genentech unit acquired from Afraxis its therapeutic business, which comprises a portfolio of compounds against undisclosed, novel targets that Afraxis said covers a range of neurology, inflammation and cancer indications. Afraxis is eligible to...
08:00 , Feb 4, 2013 |  BioCentury  |  Finance

Early bird Avalon

Early bird Avalon Avalon Ventures has hit the ground running in 2013 with two exits thus far and a third waiting in the wings. Just three weeks after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) bought Zacharon Pharmaceuticals...
02:27 , Jan 30, 2013 |  BC Extra  |  Company News

Genentech acquires Afraxis' therapeutic business

Genentech Inc. acquired from Afraxis Inc. (San Diego, Calif.) its therapeutic business, which comprises a portfolio of compounds against undisclosed, novel targets that Afraxis said covers a range of neurology, inflammation and cancer indications. Afraxis,...
07:00 , Oct 4, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer p21 Protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies suggest inhibiting PAK1 could help treat K-Ras-driven tumors. In human squamous cell...